A quick disclaimer before we jump in: This article is intended for informational purposes only and doesnt constitute medical advice or endorsement of one brand over another
YOUR SUMMER RESET STARTS HERE
Most individuals with OSA experience EDS, decreased vigilance, morning headaches, fatigue, snoring, nocturnal gasping or choking, dry mouth, drooling, nocturia, heartburn, and/or episodes of falling asleep while they are driving (leading to motor vehicle accidents) [13]
GLP-1 GIP
As of April 2026, Zepbound (tirzepatide) appears on the formulary with the following restrictions: Covered indications: Type 2 diabetes mellitus as an adjunct to diet and exercise Must be prescribed by a TRICARE-authorized provider Requires prior authorization regardless of plan type Subject to step therapy requirements (metformin, sulfonylureas, or other first-line agents must be tried first) Excluded indications: Obesity or weight management in patients without type 2 diabetes Overweight status (BMI 25 to 29.9) Metabolic syndrome without diagnosed diabetes Prediabetes (HbA1c 5.7% to 6.4%) Cardiovascular risk reduction in non-diabetic patients The distinction matters because Zepbound is FDA-approved for both chronic weight management (approved December 2023) and type 2 diabetes (approved May 2022 under the brand name Mounjaro)

In the first experiment, ovaries were collected in four seasons (winter, spring, summer and autumn), with differences in THI, and in the second experiment, ovaries were exposed to 30 C (control), 38.5 C, 40 C and 41 C